XCancer

Preliminary Trial of SNA014 for Pancreatic Cancer

Description:

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Sponsor:

SmartNuclide Biopharma

Phase:

Early Phase 1

Contacts:

Dong Dai, Doctor (CONTACT)

1014481959@qq.com

022-23340123

Government Study Link:

NCT07597772 - Click here to see study on

ClinicalTrials.gov

NODAGA-SNA006

Isotope(s):
Target(s):
  • Claudin 18.2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NODAGA
Inclusion
  • Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
  • Pathology test results from within the past year;
  • Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
Exclusion
  • Patients with uncontrolled severe infections, or those with other serious comorbidities;
  • Patients with other clearly diagnosed malignant tumours;
  • Patients deemed unsuitable for participation in this study by the investigator.
  • Patients with a life expectancy of ≤3 months;